[
  {
    "ts": null,
    "headline": "Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today",
    "summary": "The company could soon be swallowed by a very large peer -- which also happens to be a business partner.",
    "url": "https://finnhub.io/api/news?id=a71d520ebc122c9607d3c7763d7fa2a14133040fabfaee39d9a09654fe112133",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760137627,
      "headline": "Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today",
      "id": 137048956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company could soon be swallowed by a very large peer -- which also happens to be a business partner.",
      "url": "https://finnhub.io/api/news?id=a71d520ebc122c9607d3c7763d7fa2a14133040fabfaee39d9a09654fe112133"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Earnings Season Setup Remains Favorable: What to Know",
    "summary": "The big banks dominate this week's reporting docket, but we also have several bellwethers from other sectors reporting, including Johnson & Johnson, United Air Lines, and others.",
    "url": "https://finnhub.io/api/news?id=5fdff391245cd82e51984d59b6a306a5dfd4d1f704b085895c8018f92a607342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760134560,
      "headline": "Q3 Earnings Season Setup Remains Favorable: What to Know",
      "id": 137047691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The big banks dominate this week's reporting docket, but we also have several bellwethers from other sectors reporting, including Johnson & Johnson, United Air Lines, and others.",
      "url": "https://finnhub.io/api/news?id=5fdff391245cd82e51984d59b6a306a5dfd4d1f704b085895c8018f92a607342"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson recommends shareholders reject \"mini-tender\" offer by Tutanota",
    "summary": "NEW BRUNSWICK, N.J., October 10, 2025--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota’s offer price of $145.00 per share was well below the closing price of Johnson & Johnson common stock on September 26, 2025, the last",
    "url": "https://finnhub.io/api/news?id=453c1154ec5eae7c78da3f6c23aabeea012b74ad121a9b4711602ed1fe41562b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760127600,
      "headline": "Johnson & Johnson recommends shareholders reject \"mini-tender\" offer by Tutanota",
      "id": 137048958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., October 10, 2025--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota’s offer price of $145.00 per share was well below the closing price of Johnson & Johnson common stock on September 26, 2025, the last",
      "url": "https://finnhub.io/api/news?id=453c1154ec5eae7c78da3f6c23aabeea012b74ad121a9b4711602ed1fe41562b"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
    "summary": "Morgan Stanley Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=928fbb7fcab697500e0f561a667ca9b6e5114bec01b32ad4bb4ba329c8712b8d",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760127453,
      "headline": "Morgan Stanley Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
      "id": 137044591,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=928fbb7fcab697500e0f561a667ca9b6e5114bec01b32ad4bb4ba329c8712b8d"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Stock Surges on Johnson & Johnson Report",
    "summary": "Protagonist Therapeutics shares soared 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more of the exclusive ...",
    "url": "https://finnhub.io/api/news?id=b6557535e1e3359c145acd6cc48c75fe6f16ebf4270b76ee58b2a32241508cac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760126003,
      "headline": "Protagonist Stock Surges on Johnson & Johnson Report",
      "id": 137048959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Protagonist Therapeutics shares soared 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more of the exclusive ...",
      "url": "https://finnhub.io/api/news?id=b6557535e1e3359c145acd6cc48c75fe6f16ebf4270b76ee58b2a32241508cac"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and t",
    "url": "https://finnhub.io/api/news?id=2a27e7e5d63c72c1b5aad86ef564c1fa8c9705a7afe66c986b47282a801423af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760125090,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 137048960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and t",
      "url": "https://finnhub.io/api/news?id=2a27e7e5d63c72c1b5aad86ef564c1fa8c9705a7afe66c986b47282a801423af"
    }
  },
  {
    "ts": null,
    "headline": "PRESS: Johnson & Johnson in talks to buy Protagonist Therapeutics",
    "summary": "PRESS: Johnson & Johnson in talks to buy Protagonist Therapeutics",
    "url": "https://finnhub.io/api/news?id=8f9bf9a443fa31c38d93790332cdbb04750b5dd230967c33bdae4b5601e3d8b9",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760121862,
      "headline": "PRESS: Johnson & Johnson in talks to buy Protagonist Therapeutics",
      "id": 137044172,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8f9bf9a443fa31c38d93790332cdbb04750b5dd230967c33bdae4b5601e3d8b9"
    }
  },
  {
    "ts": null,
    "headline": "Trump's China tariff threat sinks stocks, Applied Digital surges",
    "summary": "Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition talks with Johnson & Johnson (JNJ), and Applied Digital (APLD) stock is climbing after posting its fiscal Q1 earnings report. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=8e625c8fbb9a933b41ed524a17b055c57dbbd0e460f40de4c8290c63dbbf1e7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760120475,
      "headline": "Trump's China tariff threat sinks stocks, Applied Digital surges",
      "id": 137048961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition talks with Johnson & Johnson (JNJ), and Applied Digital (APLD) stock is climbing after posting its fiscal Q1 earnings report. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=8e625c8fbb9a933b41ed524a17b055c57dbbd0e460f40de4c8290c63dbbf1e7b"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Friday Afternoon",
    "summary": "Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care",
    "url": "https://finnhub.io/api/news?id=ebfa27236efd8b0a03f06d8f5003b3b9af448ed02da43fe5222a06419786e301",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760119656,
      "headline": "Sector Update: Health Care Stocks Decline Friday Afternoon",
      "id": 137048962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care",
      "url": "https://finnhub.io/api/news?id=ebfa27236efd8b0a03f06d8f5003b3b9af448ed02da43fe5222a06419786e301"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Gainers",
    "summary": "Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F",
    "url": "https://finnhub.io/api/news?id=07029b7765ab042a560c35eda7418d6a03583153f68c48ec83b03db52c07b836",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760117221,
      "headline": "Top Midday Gainers",
      "id": 137048963,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F",
      "url": "https://finnhub.io/api/news?id=07029b7765ab042a560c35eda7418d6a03583153f68c48ec83b03db52c07b836"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.",
    "summary": "The recent cavalcade of biotech deals continued Friday morning, when  Bristol Myers Squibb  said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines.  Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year.  The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.",
    "url": "https://finnhub.io/api/news?id=7d6a7d87f2d7d4a5725b458303ab18f2cf290aff6d4a485d575f23dc5f813107",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760113140,
      "headline": "Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.",
      "id": 137043167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The recent cavalcade of biotech deals continued Friday morning, when  Bristol Myers Squibb  said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines.  Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year.  The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.",
      "url": "https://finnhub.io/api/news?id=7d6a7d87f2d7d4a5725b458303ab18f2cf290aff6d4a485d575f23dc5f813107"
    }
  },
  {
    "ts": null,
    "headline": "Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know",
    "summary": "J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.",
    "url": "https://finnhub.io/api/news?id=3c17c45a6ee2eaa9d6781ef274d33e0e6f7aa80a0e08f7cac17b916900e76dad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760112600,
      "headline": "Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know",
      "id": 137048965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.",
      "url": "https://finnhub.io/api/news?id=3c17c45a6ee2eaa9d6781ef274d33e0e6f7aa80a0e08f7cac17b916900e76dad"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Trump Threatens 'Massive' Tariff Raise on China; Nvidia Chips Face Higher Scrutiny at China Customs",
    "summary": "All three major US stock indexes were in the red around midday trading Friday, with the Nasdaq Compo",
    "url": "https://finnhub.io/api/news?id=74bf0c39b0562e42be9291fb5a35223d90ba924440d89c9bd0439ae5dd88bd83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760111631,
      "headline": "Top Midday Stories: Trump Threatens 'Massive' Tariff Raise on China; Nvidia Chips Face Higher Scrutiny at China Customs",
      "id": 137041253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were in the red around midday trading Friday, with the Nasdaq Compo",
      "url": "https://finnhub.io/api/news?id=74bf0c39b0562e42be9291fb5a35223d90ba924440d89c9bd0439ae5dd88bd83"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics stock surges after J&J acquisition talks report",
    "summary": "Investing.com -- Protagonist Therapeutics (NASDAQ:PTGX) stock spiked 10% before being halted for volatility after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the biotech company.",
    "url": "https://finnhub.io/api/news?id=69e9064bbfd12c1b85b1b29a6a5354623f30685728dae2ba3b7191d57bc2c342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760111603,
      "headline": "Protagonist Therapeutics stock surges after J&J acquisition talks report",
      "id": 137041479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Protagonist Therapeutics (NASDAQ:PTGX) stock spiked 10% before being halted for volatility after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the biotech company.",
      "url": "https://finnhub.io/api/news?id=69e9064bbfd12c1b85b1b29a6a5354623f30685728dae2ba3b7191d57bc2c342"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson in Talks to Buy Protagonist Therapeutics",
    "summary": "Johnson & Johnson  is in talks to buy  Protagonist Therapeutics  in a deal that would solidify the companies’ existing partnership, according to people familiar with the matter.  A deal is not guaranteed and the exact details being discussed couldn’t be learned, the people said.  Protagonist had a market value of over $4 billion as of Thursday’s close.",
    "url": "https://finnhub.io/api/news?id=07453f6700b3ef158df7aab4a7e8246c98556559b515b385465743110cb5669d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760109180,
      "headline": "Johnson & Johnson in Talks to Buy Protagonist Therapeutics",
      "id": 137041480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson  is in talks to buy  Protagonist Therapeutics  in a deal that would solidify the companies’ existing partnership, according to people familiar with the matter.  A deal is not guaranteed and the exact details being discussed couldn’t be learned, the people said.  Protagonist had a market value of over $4 billion as of Thursday’s close.",
      "url": "https://finnhub.io/api/news?id=07453f6700b3ef158df7aab4a7e8246c98556559b515b385465743110cb5669d"
    }
  },
  {
    "ts": null,
    "headline": "Big Banks Gear Up to Report Q3 Earnings",
    "summary": "Big Banks Gear Up to Report Q3 Earnings",
    "url": "https://finnhub.io/api/news?id=722b947539dd1c6bb68d6a345fe93a6c273067882448129c0ea936fe7f7f7e39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760108760,
      "headline": "Big Banks Gear Up to Report Q3 Earnings",
      "id": 137041258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Big Banks Gear Up to Report Q3 Earnings",
      "url": "https://finnhub.io/api/news?id=722b947539dd1c6bb68d6a345fe93a6c273067882448129c0ea936fe7f7f7e39"
    }
  },
  {
    "ts": null,
    "headline": "Pre-markets Up Slightly to Start Friday Trading",
    "summary": "We're devoid of major market catalysts until Q3 earnings season builds next week, when the Big Banks begin reporting on Tuesday morning.",
    "url": "https://finnhub.io/api/news?id=2c493eefb86e151027a9b40982f12479ab672463e91e830c95e4727da04f6b03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760106720,
      "headline": "Pre-markets Up Slightly to Start Friday Trading",
      "id": 137041262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We're devoid of major market catalysts until Q3 earnings season builds next week, when the Big Banks begin reporting on Tuesday morning.",
      "url": "https://finnhub.io/api/news?id=2c493eefb86e151027a9b40982f12479ab672463e91e830c95e4727da04f6b03"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 17 abstracts featuring new clinical and real-world data will be presented at the annual European College of Neuropsychopharmacology (ECNP) Congress, taking place October 11-14 in Amsterdam, The Netherlands. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD), treatment-resistant depression (TRD), and schizophrenia.",
    "url": "https://finnhub.io/api/news?id=dafcc451dbf27f84a668fe51ffcffec5617ddb5bccb586b7e263a29e3cd9cf79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760095800,
      "headline": "Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress",
      "id": 137041483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 17 abstracts featuring new clinical and real-world data will be presented at the annual European College of Neuropsychopharmacology (ECNP) Congress, taking place October 11-14 in Amsterdam, The Netherlands. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD), treatment-resistant depression (TRD), and schizophrenia.",
      "url": "https://finnhub.io/api/news?id=dafcc451dbf27f84a668fe51ffcffec5617ddb5bccb586b7e263a29e3cd9cf79"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced",
    "summary": "Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. See why JNJ stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=deb2c680d3ed21229cdd1b78c9fd8288f8598fe15ccff4e8ffdb6af3285956ec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760082523,
      "headline": "Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced",
      "id": 137040347,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428797069/image_1428797069.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. See why JNJ stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=deb2c680d3ed21229cdd1b78c9fd8288f8598fe15ccff4e8ffdb6af3285956ec"
    }
  }
]